MedPath

Tagged News

Neurovation Labs Secures Patent for Novel PTSD Biomarker Detection Technology

AINeurologyPrecision Medicine
• Neurovation Labs has been granted U.S. Patent No. 12,274,761 for technology that detects GluA1-containing AMPA receptors in the brain, enabling objective PTSD diagnosis.
• The patented radiological imaging device represents a significant advancement in mental health diagnostics by providing a physiological biomarker for a condition traditionally diagnosed through subjective assessments.
• Beyond PTSD, Neurovation Labs is exploring applications of this technology for other neurological conditions including traumatic brain injury, Alzheimer's disease, and epilepsy.

Roche Adjusts Tominersen Dosing in GENERATION HD2 Trial for Huntington's Disease

Neurology
  • Roche has announced modifications to its GENERATION HD2 trial for tominersen, a huntingtin-lowering therapy for Huntington's disease, following a scheduled review by an independent data monitoring committee.
  • The trial will continue with the higher 100mg dose only, discontinuing the 60mg dose arm, as the higher dose was deemed more likely to demonstrate clinical benefit while maintaining a favorable safety profile.
  • This development represents a positive step forward for tominersen, which previously faced setbacks when its GENERATION HD1 trial was halted in 2021 due to safety concerns.

GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease

NCT05686551Active, Not RecruitingPhase 2
Hoffmann-La Roche
Posted 2/3/2023

A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Participants With Manifest Huntington's Disease

NCT03761849CompletedPhase 3
Hoffmann-La Roche
Posted 1/23/2019

Study Reveals Significant Diagnostic Delays for Minority Patients with Generalized Myasthenia Gravis

Rare DiseaseNeurology
  • Project ASPIRE research reveals racial and ethnic minority patients with generalized myasthenia gravis (gMG) face nearly four-month longer diagnostic delays compared to white patients, despite seeking care at similar timeframes.
  • Key barriers to timely gMG diagnosis include poor symptom recognition by both patients and physicians, limited access to specialists, and challenges with medical record transfers between healthcare systems.
  • Minority patients reported significantly higher stress levels during their diagnostic journey, with nearly double the percentage rating their experience as "very stressful" compared to white patients.

Annexon's Tanruprubart Shows Rapid and Durable Improvements in Guillain-Barré Syndrome Phase III Trial

NeurologyMonoclonal Antibody
  • Tanruprubart demonstrated significant functional improvements in Guillain-Barré syndrome patients as early as one week after treatment, with patients 14 times more likely to show improved mobility versus placebo.
  • The monoclonal antibody targeting C1q protein maintained durable benefits through 26 weeks, with twice as many treated patients achieving full recovery compared to placebo.
  • If approved, tanruprubart could address a significant unmet need for the estimated 7,000 U.S. and 15,000 EU patients diagnosed with GBS annually, potentially representing a $1 billion market opportunity.

Efficacy and Safety of ANX005 in Subjects With Guillain-Barré Syndrome

NCT04701164CompletedPhase 3
Annexon, Inc.
Posted 12/17/2020

Alzinova Secures Funding for Phase II Alzheimer's Drug Trial Preparations

Neurology
• Alzinova has successfully raised capital to advance preparations for Phase II clinical trials of its Alzheimer's disease therapeutic candidate, following promising early-stage results.
• The company is now fully focused on Phase II trial preparations, as highlighted in Carnegie's commissioned research reports and confirmed in Alzinova's Q1 review.
• This development represents a significant milestone in Alzinova's clinical pipeline, potentially offering a new approach to addressing the unmet needs in Alzheimer's disease treatment.

Specialty Pharmacists Drive Significant Improvements in Non-MS Neurology Care, Study Shows

Neurology
  • A single-center study at Vanderbilt University Medical Center found specialty pharmacists performed over 2,000 interventions across 741 neurology patients in just three months, with 98% of recommendations accepted by providers.
  • The most common interventions included medication changes (35%), patient counseling (10%), and care coordination (10%), demonstrating pharmacists' critical role in preventing treatment delays.
  • Researchers utilized a standardized 4-point impact scale, with most interventions (76%) rated as moderately impactful, suggesting significant improvements to patient quality of life and medication adherence.

Tofersen Shows Promise in Slowing Progression of SOD1 Motor Neuron Disease

Rare DiseaseNeurology
  • Tofersen, developed by Biogen, has demonstrated significant efficacy in slowing the progression of MND in patients with the SOD1 genetic mutation, offering a breakthrough in treatment for this previously untreatable condition.
  • Despite being available through Biogen's Extended Access Program at no cost, some patients face barriers to access as the NHS struggles with administration costs and capacity for the monthly lumbar puncture procedure.
  • Clinical trials, including the ATLAS study, show particularly promising results when treatment begins before symptom onset, with some patients remaining symptom-free despite elevated neurofilament levels indicating disease activation.

Neurogen Biomarking Partners with NeuroX to Revolutionize Early Alzheimer's Detection

Neurology
  • Neurogen Biomarking and NeuroX have formed a strategic partnership to accelerate early detection of Alzheimer's disease through an innovative patient-initiated platform combining blood biomarker testing and AI-enhanced cognitive assessments.
  • The collaboration addresses critical gaps in neurological care, with NeuroX's board-certified neurologists providing telehealth support that reduces typical specialist wait times from months to weeks for the 92% of Americans with MCI who remain undiagnosed.
  • Launching commercially in 2025, the integrated platform offers a comprehensive patient journey including digital cognitive assessment, at-home blood biomarker testing for ptau217, and personalized brain health action plans developed by specialists.

Regeneron Leads $60 Million Consortium to Accelerate UK Biobank Genome Sequencing for Alzheimer's and Parkinson's Drug Discovery

Drug DiscoveryNeurology
• Regeneron has formed a consortium with AbbVie, Alnylam, AstraZeneca, Biogen, and Pfizer, with each company committing $10 million to accelerate sequencing of 500,000 UK Biobank genomes by end of 2019. • The project aims to identify new biological targets for drug development, particularly for neurological diseases like Alzheimer's and Parkinson's, where current failure rates exceed 90%. • Regeneron's automated sequencing capabilities through its Genetics Center have dramatically reduced processing time, potentially revolutionizing drug discovery by linking genetic data with health records from 500,000 volunteers. • After an exclusive access period for consortium members, all sequencing data and research findings will be made publicly available to the broader scientific community.

Riliprubart Shows Promise as First-in-Class Treatment for Chronic Inflammatory Demyelinating Polyneuropathy

Rare DiseaseNeurologyMonoclonal Antibody
  • Sanofi's riliprubart demonstrated significant disease-controlling benefits across all patient cohorts in a Phase 2 study for chronic inflammatory demyelinating polyneuropathy (CIDP), including those who failed standard treatments.
  • The complement C1s inhibitor showed sustained efficacy for up to 48 weeks, with 87-92% of participants experiencing improvement or disease stabilization after 24 weeks of treatment.
  • Riliprubart reduced neurofilament light chain levels by 35% across all cohorts, suggesting potential reduction in nerve damage, while also improving patient-reported fatigue and quality of life outcomes.

A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

NCT06290141RecruitingPhase 3
Sanofi
Posted 8/21/2024

A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work

NCT06290128RecruitingPhase 3
Sanofi
Posted 7/12/2024

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.